Literature DB >> 8392026

Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease.

N Kato1, O Yokosuka, K Hosoda, Y Ito, M Ohto, M Omata.   

Abstract

We developed a quantitative method of hepatitis C virus RNA by competitive reverse transcription-polymerase chain reaction. With this method, 36 patients with type C chronic liver disease were analyzed for the copy number of circulating hepatitis C virus in 50 microliters of serum. The amounts of hepatitis C virus RNA ranged from 10(1) to 10(7) copies in the 36 patients. The average amount of hepatitis C virus RNA was 10(3.3 +/- 2.2) copies in 12 patients with chronic persistent hepatitis, 10(5.7 +/- 1.6) copies in 12 patients with chronic active hepatitis and 10(6.0 +/- 1.6) copies in 12 patients with cirrhosis (including 4 patients with hepatocellular carcinoma). The amount of hepatitis C virus RNA in serum was significantly less in patients with chronic persistent hepatitis than in patients with chronic active hepatitis or cirrhosis (p < 0.01), and it tended to increase according to the progression of histopathological changes of the liver. Furthermore, it was revealed that the amount of hepatitis C virus RNA became exponentially larger as the term from infection became longer. Quantification of hepatitis C virus RNA by competitive reverse transcription-polymerase chain reaction may have many applications for the study of clinical features of hepatitis C virus infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392026

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  49 in total

1.  Correlates of high hepatitis C virus RNA load in a cohort of HIV-negative and HIV-positive individuals with haemophilia.

Authors:  S M Gadalla; L R Preiss; M E Eyster; J J Goedert
Journal:  J Viral Hepat       Date:  2011-03       Impact factor: 3.728

2.  Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C.

Authors:  A Sánchez-Quijano; J Andreu; F Gavilán; F Luque; M A Abad; B Soto; J Muñoz; J M Aznar; M Leal; E Lissen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

Review 3.  Hepatitis C: diagnosis and treatment.

Authors:  I Scotiniotis; C A Brass; P F Malet
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

4.  Quantification of serum hepatitis C virus core protein level in patients chronically infected with different hepatitis C virus genotypes.

Authors:  E Orito; M Mizokami; T Tanaka; J Y Lau; K Suzuki; M Yamauchi; Y Ohta; A Hasegawa; S Tanaka; M Kohara
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

Review 5.  Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection.

Authors:  M Clementi; S Menzo; P Bagnarelli; A Valenza; S Paolucci; R Sampaolesi; A Manzin; P E Varaldo
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

6.  Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays.

Authors:  W K Roth; J H Lee; B Rüster; S Zeuzem
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

7.  Prevalence of hepatitis C virus genotypes in southern Italy.

Authors:  S Cicciarello; G Borgia; J Crowell; R Ciampi; R Cerini; R Orlando; M Mainolfi; L Reynaud; M Milano; M Piazza
Journal:  Eur J Epidemiol       Date:  1997-01       Impact factor: 8.082

8.  Serum levels of soluble interleukin-2 receptors and effects of interferon-alpha for patients with chronic hepatitis C virus.

Authors:  J Hayashi; Y Kishihara; K Yamaji; E Yoshimura; M Ohmiya; Y Tani; H Ikematsu; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

9.  "Rebound" phenomenon of hepatitis C viremia after interferon therapy in "relapsed" patients with chronic hepatitis C.

Authors:  H Hanada; K Hino; K Fujii; M Okazaki; K Okita
Journal:  J Gastroenterol       Date:  1995-06       Impact factor: 7.527

10.  Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.

Authors:  Pascal Veillon; Christopher Payan; Gastón Picchio; Michèle Maniez-Montreuil; Philippe Guntz; Françoise Lunel
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.